杨博谦,李卫东

甲状腺乳头状癌（papillary thyroid carcinoma，PTC）作为甲状腺癌的主要类型，源自甲状腺滤泡上皮细胞的分化，占据了此类癌症病例的绝大多数。桥本甲状腺炎（Hashimoto thyroiditis，HT）则是一种器官特异性的自身免疫性疾病，在甲状腺炎病例中占据了显著地位。近年来，HT和PTC的患病率均有所上升，约10%至50%的PTC患者同时被诊断出患有HT。深入探究HT与PTC之间的潜在联系，不仅有助于我们更全面地理解PTC的发病机理，还能为开发新的治疗策略奠定理论基础。

甲状腺乳头状癌；桥本甲状腺炎；综述

[1] 王苹.桥本甲状腺炎的病因和治疗研究进展[J].医学理论与实践,2022,35(15):2556-2558+2555. [2] 甲状腺癌诊疗规范(2018 年版)[J].中华普通外科学文献(电子版),2019,13(01):1-15. [3] 雷林,尚庆刚,刘维耿,等.深圳市 2001~2015 年甲状腺癌发病现状和趋势分析[J].中国肿瘤,2019,28(7):504-508. [4] Lai, X, Xia, Y, Zhang, B, et al. A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. Oncotarget. 2017; 8 (37): 62414-62424. [5] DAILEY, ME, LINDSAY, S, SKAHEN, R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955; 70 (2): 291-7. [6] Pagano, L, Mele, C, Sama, MT, et al. Thyroid cancer phenotypes in relation to inflammation and autoimmunity. FRONT BIOSCI-LANDMRK. 2018; 23 (12): 2267-2282. [7] Al Hamad, M, Lasrado, S, Albarbari, HS, et al. Research productivity in the genetics of papillary thyroid carcinoma (1991-2020): a bibliometric analysis. Acta Biomed. 2022; 93 (3): e2022086. [8] Landa, I, Pozdeyev, N, Knauf, JA, et al. Genetics of Human Thyroid Cancer Cell Lines-Response. CLIN CANCER RES. 2019; 25 (22): 6883-6884. [9] Uhliarova, B, Hajtman, A. Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma. BRAZ J OTORHINOLAR. 2017; 84 (6): 729-735. [10] Xu JY, Ding K, Mu L, et al. Hashimoto’s thyroiditis: a “DoubleEdged Sword” in thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 801925. [11] 吴佳奇,王虹,杜琳瑶,等.桥本甲状腺炎合并甲状腺乳头状癌超声特征与颈部淋巴结转移的相关性研究.哈尔滨医科大学学报,2018,52(4):387-390. [12] Grani, G, Ramundo, V, Verrienti, A, et al. Thyroid hormone therapy in differentiated thyroid cancer. ENDOCRINE. 2019; 66 (1): 43-50. [13] Xu S, Huang H, Qian J, Liu Y, Huang Y, Wang X, Liu S, Xu Z, Liu J. Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes. JAMA Netw Open. 2021 Jul 1;4(7):e2118526. doi: 10.1001/jamanetworkopen.2021.18526. PMID: 34313737; PMCID: PMC8317012. [14] Choi, EK, Chong, A, Ha, JM, et al. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. CLIN ENDOCRINOL. 2017; 87 (1): 73-79. [15] 谭碧星.桥本氏甲状腺炎背景下甲状腺乳头状癌的超声特征､BRAF V600E 突变及侵袭性情况的研究.张家口:河北北方学院,2022. [16] Shen, CT, Zhang, XY, Qiu, ZL, et al. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? ENDOCRINE. 2017; 58 (1): 176-183. [17] Song, E, Oh, HS, Jeon, MJ, et al. The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma. INT J CANCER. 2018; 144 (6): 1414-1420.

点击下载PDF